litlas
Log inCreate account

Hiroji Iwata

Active 1996–2025

226
Papers
47,914
Citations
89
h-index
213
i10-index

Citations

Citations per year for Hiroji Iwata1964: 2 citations1971: 1 citations1993: 2 citations1996: 1 citations1997: 1 citations1998: 10 citations1999: 12 citations2000: 6 citations2001: 12 citations2002: 12 citations2003: 15 citations2004: 20 citations2005: 20 citations2006: 73 citations2007: 109 citations2008: 107 citations2009: 120 citations2010: 136 citations2011: 106 citations2012: 116 citations2013: 144 citations2014: 107 citations2015: 139 citations2016: 232 citations2017: 237 citations2018: 308 citations2019: 1,327 citations2020: 2,262 citations2021: 2,847 citations2022: 2,710 citations2023: 2,304 citations2024: 3,188 citations2025: 1,586 citations2026: 40 citations1965–1970: no citations, so these years are not shown1972–1992: no citations, so these years are not shown1994–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,754 citing papers, 22.3% of this breakdownChina: 2,375 citing papers, 11.1% of this breakdownItaly: 1,304 citing papers, 6.1% of this breakdownUnited Kingdom: 1,170 citing papers, 5.5% of this breakdownGermany: 987 citing papers, 4.6% of this breakdownFrance: 893 citing papers, 4.2% of this breakdownSpain: 827 citing papers, 3.9% of this breakdownJapan: 771 citing papers, 3.6% of this breakdownCanada: 747 citing papers, 3.5% of this breakdownAustralia: 608 citing papers, 2.9% of this breakdownSouth Korea: 527 citing papers, 2.5% of this breakdownBelgium: 514 citing papers, 2.4% of this breakdown
0%22.3%Other 27.4%

Institutions

Fields

  • Medicine63.9%
  • Biochemistry, Genetics and Molecular Biology27.9%
  • Immunology and Microbiology3.2%
  • Engineering1.1%
  • Materials Science1%
  • Computer Science0.9%
  • Other2%

Topics

  • HER2/EGFR in Cancer Research8.7%
  • Advanced Breast Cancer Therapies7.3%
  • Breast Cancer Treatment Studies6.5%
  • Cancer Immunotherapy and Biomarkers6.4%
  • Cancer Genomics and Diagnostics3%
  • Monoclonal and Polyclonal Antibodies Research2.8%
  • Other65.3%

Coauthors

All papers

Open in search
  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Authors: Peter Schmid, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Roberto Hegg, Seock‐Ah Im, Gail S. Wright, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Roel Funke, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - New England Journal of Medicine 2018 cited by 4,369

  2. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Authors: Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, PierFranco Conte, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric - New England Journal of Medicine 2019 cited by 2,572

  3. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    Authors: Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung‐Bae Kim, Kenji Tamura, Fabrice André, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani, Joohyuk Sohn, Neelima Denduluri, Christophe Perrin, Kenjiro Aogi, Eriko Tokunaga, Seock‐Ah Im, Keun Seok Lee, Sara A. Hurvitz, Javier Cortés, Caleb Lee, Shuquan Chen, Lin Zhang, Javad Shahidi, Antoine Yver, Ian E. Krop - New England Journal of Medicine 2019 cited by 1,973

  4. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

    Authors: Javier Cortés, Hope S. Rugo, David W. Cescon, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, José Manuel Pérez-García, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gokmen, Sherene Loi, Zifang Guo, Xuan Zhou, Vassiliki Karantza, Wilbur Pan, Peter Schmid - New England Journal of Medicine 2022 cited by 1,096

  5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

    Authors: Javier Cortés, David W. Cescon, Hope S. Rugo, Zbigniew Nowecki, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, Esther Holgado, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gökmen, Sherene Loi, Zifang Guo, Jing Zhao, Gursel Aktan, Vassiliki Karantza, Peter Schmid, F. Vidal Luis, Gomez Abuin Gonzalo, Diego Kaen, Kowalwszyn Ruben, Molina Matias, Varela Mirta, Sally Baron-Hay, Begbie Stephen, Clingan Philip, Loi Sherene, Sabanathan Dhanusha, Andrea Gombos, Donatienne Taylor, Carlos Barrios, Leandro Brust, Costa Fabiano, de Freitas Junior Ruffo, Roberto Hegg, Lacerda Domicio Carvalho, Lissa Fernando Cezar Toniazzi, Rocha Roberto Odebrecht, Scalabrini Neto Antonio Orlando, Silva Felipe, Cescon David, Danielle Charpentier, Ferrario Cristiano, Xinni Song, Yu Joanne, Alejandro Acevedo, Gallardo Carlos, Salas Claudio, Sanchez Cesar, Eduardo Yañez, Gomez Diaz Alvaro, Sanchez Jesus, Holeckova Petra, Kral Zdenek, Bohuslav Melichar, Katarína Petráková, Prausova Jana, Vesna Glavicic, Jakobsen Erik, Jensen Jeanette, Søren Linnet, Tamás Lörincz, Bonnefoi Herve, Isabelle Desmoulins, Goncalves Anthony, Hardy-Bessard Anne-Claire, Luís Teixeira, Blohmer Jens-Uwe, Fasching Peter, Dirk Forstmeyer, Nadia Harbeck, Huober Jens, Kaczerowsky Flores de Sousa Anna, Kurbacher Christian, Sibylle Loibl, Lueftner Diana, Park-Simon Tjoung-Won, Schumann Raquel Von, Pauline Wimberger, Chow Louis, Kwong Ava, Ngan Kai Cheong Roger, Peter Arkosy, Tibor Csőszi, Zsuzsanna Kahán, Landherr László, Mahr Karoly, Gábor Rubovszky, Crown John, Kelly Catherine, O'Reilly Seamus, Saverio Cinieri, DAlessio Antonietta, Ricevuto Enrico, Tomoyuki Aruga, Takaaki Fujii, Inoue Kenichi and 127 more - The Lancet 2020 cited by 1,800

  6. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

    Authors: Javier Cortés, Sung-Bae Kim, Wei-Pang Chung, Seock-Ah Im, Yeon Hee Park, Roberto Hegg, Min Hwan Kim, Ling-Ming Tseng, Vanessa Petry, Chi-Feng Chung, Hiroji Iwata, Erika Hamilton, Giuseppe Curigliano, Binghe Xu, Chiun-Sheng Huang, Jee Hyun Kim, Joanne W.Y. Chiu, Jose Luiz Pedrini, Caleb Lee, Yali Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz - New England Journal of Medicine 2022 cited by 1,124

  7. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    Authors: Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung, Seock‐Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altıntaş, Jan‐Willem Henning, Giuseppe Curigliano, José Manuel Pérez-García, Sung‐Bae Kim, Vanessa Petry, Chiun‐Sheng Huang, Wěi Li, Jean‐Sébastien Frenel, Silvia Antolín, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés - The Lancet 2022 cited by 642

  8. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

    Authors: Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L. Telli, Cristiano Ferrario, Kevin Punie, Frédérique Penault-Llorca, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Vidya Maiya, Luciana Molinero, Jane Yuet Ching Hui, Nadia Harbeck - The Lancet 2020 cited by 1,060

  9. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

    Authors: Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young‐Hyuck Im, Eun Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock‐Ah Im, Byeong‐Woo Park, Sung‐Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong Hwa Park, Hironobu Sasano, Yasuo Ohashi, Masakazu Toi - New England Journal of Medicine 2017 cited by 1,887

  10. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Peter Schmid, Hope S. Rugo, Sylvia Adams, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Vidya Maiya, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - The Lancet Oncology 2019 cited by 1,198

  11. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

    Authors: Shanu Modi, Haeseong Park, Rashmi K. Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno‐Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles H. Redfern, Ian E. Krop, Caleb Lee, Yoshihiko Fujisaki, Masahiro Sugihara, Lin Zhang, Javad Shahidi, Shunji Takahashi - Journal of Clinical Oncology 2020 cited by 817

  12. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Authors: Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, María Koehler, Dennis J. Slamon - The Lancet Oncology 2016 cited by 1,822

  13. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Authors: Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro, Igor Bondarenko, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Fabrice André, Kathy Puyana Theall, Xin Huang, C. Giorgetti, Cynthia Huang Bartlett, Massimo Cristofanilli - New England Journal of Medicine 2018 cited by 1,293

  14. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

    Authors: Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Dièras, Hiroji Iwata, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Eric P. Winer, Shilpen Patel, Volkmar Henschel, A. Swat, Manika Kaul, Luciana Molinero, Shilpen Patel, S.Y. Chui, P. Schmid - Annals of Oncology 2021 cited by 468

  15. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Authors: Nicholas C. Turner, Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Cynthia Huang Bartlett, Ke Zhang, C. Giorgetti, Sophia Randolph, María Koehler, Massimo Cristofanilli - New England Journal of Medicine 2015 cited by 1,586

  16. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    Authors: Fabrice André, Eva Ciruelos, Dejan Juric, Sibylle Loibl, Mario Campone, Ingrid A. Mayer, Gábor Rubovszky, Toshinari Yamashita, Bella Kaufman, Yen‐Shen Lu, Kenichi Inoue, Zsuzsanna Pápai, Masato Takahashi, Farhat Ghaznawi, David Mills, Mathilde Kaper, Michelle C. Miller, PierFranco Conte, Hiroji Iwata, Hope S. Rugo - Annals of Oncology 2020 cited by 599

  17. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

    Authors: Stephen Johnston, Miguel Martín, Angelo Di Leo, Seock‐Ah Im, Ahmad Awada, Tammy Forrester, Martin Frenzel, Molly Catherine Hardebeck, Joanne Cox, Susana Barriga, Masakazu Toi, Hiroji Iwata, Matthew P. Goetz - npj Breast Cancer 2019 cited by 676

  18. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

    Authors: Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber - New England Journal of Medicine 2005 cited by 5,098

  19. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

    Authors: Junji Tsurutani, Hiroji Iwata, Ian E. Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles H. Redfern, Kenji Tamura, Trisha M. Wise‐Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T. Li - Cancer Discovery 2020 cited by 353

  20. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

    Authors: Sylvia Adams, Sherene Loi, Deborah Toppmeyer, David W. Cescon, Michelino De Laurentiis, Rita Nanda, Eric P. Winer, Hirofumi Mukai, Kenji Tamura, Anne Armstrong, M.C. Liu, Hiroji Iwata, L Ryvo, Pauline Wimberger, Hope S. Rugo, Antoinette R. Tan, Lin Jia, Yu Ding, Vassiliki Karantza, Peter Schmid - Annals of Oncology 2018 cited by 631

  21. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

    Authors: Leisha A. Emens, Luciana Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Véronique Dièras, Hiroji Iwata, Carlos H. Barrios, M. Nechaeva, Anh Nguyen‐Duc, Jane Yuet Ching Hui, Amreen Husain, Eric P. Winer, Sylvia Adams, Peter Schmid - JNCI Journal of the National Cancer Institute 2021 cited by 306

  22. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

    Authors: Charles A. Powell, Shanu Modi, Hiroji Iwata, Shunji Takahashi, Egbert F. Smit, Salvatore Siena, D.-Y. Chang, E. Macpherson, A. Qin, Jasmeet Singh, Corina Taitt, Norah J. Shire, D. Ross Camidge - ESMO Open 2022 cited by 231

  23. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

    Authors: Kenji Tamura, Junji Tsurutani, Shunji Takahashi, Hiroji Iwata, Ian E. Krop, Charles H. Redfern, Yasuaki Sagara, Toshihiko Doi, Haeseong Park, Rashmi K. Murthy, Rebecca Redman, Takahiro Jikoh, Caleb Lee, Masahiro Sugihara, Javad Shahidi, Antoine Yver, Shanu Modi - The Lancet Oncology 2019 cited by 350

  24. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

    Authors: Massimo Cristofanilli, Hope S. Rugo, Seock‐Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O’Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner - Clinical Cancer Research 2022 cited by 198